Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer

Por Heerma van Voss, Marise R., Brilliant, Justin D., Vesuna, Farhad, Bol, Guus M., van der Wall, Elsken, van Diest, Paul J., Raman, Venu
Publicado no Med Oncol (2017)

Global Effects of DDX3 Inhibition on Cell Cycle Regulation Identified by a Combined Phosphoproteomics and Single Cell Tracking Approach

Por Heerma van Voss, Marise R., Kammers, Kai, Vesuna, Farhad, Brilliant, Justin, Bergman, Yehudit, Tantravedi, Saritha, Wu, Xinyan, Cole, Robert N., Holland, Andrew, van Diest, Paul J., Raman, Venu
Publicado no Transl Oncol (2018)

Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer

Por van Voss, Marise R. Heerma, Vesuna, Farhad, Trumpi, Kari, Brilliant, Justin, Berlinicke, Cynthia, de Leng, Wendy, Kranenburg, Onno, Offerhaus, Johan G., Bürger, Horst, van der Wall, Elsken, van Diest, Paul J., Raman, Venu
Publicado no Oncotarget (2015)